

Corporate Dossier



TABLE OF CONTENTS

01. Who we are

- Introduction
- Global health
- History and evolution
- #HIPRApeople
- HIPRA around the world

02. What we do

- Human health
- Animal health
- Without innovation there is no project
- Sustainability
- Corporate Social Responsibility



Who
we are

01.

HIPRA is a biotechnological pharmaceutical company focused on prevention for animal and human health. With **more than 50 years of experience**, it has a wide range of highly innovative vaccines and an advanced diagnostic service. In line with its claim “Building Immunity for a Healthier World”, HIPRA affirms its commitment to providing solutions that improve global health.

Research is at the core of its expertise. Sixteen per cent of HIPRA’s staff and 10% of its annual turnover are devoted to R&D and Recording. With a unique organisational model, **it controls internally all the processes in the value chain, generating unique** know-how and becoming a benchmark in the research, production and marketing of biologics.

HIPRA has launched a total of 22 biotech vaccines in the last ten years, more than any other company.

To add value to its vaccination expertise, the company also develops **medical devices** and **traceability services**.



Global health

HIPRA has a solid international presence with its own subsidiaries in **40 countries, 11 diagnostic centres, three R&D centres and six production centres** located strategically in Europe and America. Its extensive distribution network allows its solutions to be available across all **five continents** to improve human and animal health.

**Working to build immunity for a healthier world,
using all our enthusiasm, knowledge and talent**

+ 50 years

of experience

Ranked 5th

animal health vaccines

108 vaccines

in our portfolio

6 production

centres

50 projects

in our pipeline

> 2,400

workers

History and evolution

Its origins go back to **1971** when a group of young entrepreneurs acquired a small laboratory in Madrid founded in 1954 called HIPRA (after the surnames of its former creators: Hidalgo and Prada), and moved to Amer (Girona).

The year **1991**, with a workforce of 100 people and turnover of 10 million euros, was a crucial year in HIPRA's history. A new, highly motivated management team redefined the company's expansion policy. Thus began an important period of technical and commercial expansion.

From **2000** onwards, the internationalisation of HIPRA began with the establishment of its own subsidiaries around the world. HIPRA currently has commercial subsidiaries in 40 countries, three research centres and six production centres located strategically in Europe and America. Its extensive distribution network covers all five continents.

In **2009**, it refined its strategic positioning, with the clear mission of being the world leader in prevention, with differentiating and innovative products, and therefore it stopped investing in pharmacological products.

In **2020**, and in the context of the COVID-19 pandemic, HIPRA faced a new challenge, using its extensive experience in high-tech vaccines to develop a vaccine against this new virus.

In **2021**, the new Human Health Division was created to develop new innovative products. In the same year, it acquired GoodGut, a biotech start-up devoted to the research and development of diagnostic tests for digestive illnesses.

#HIPRApeople

HIPRA is made up of a multicultural and multidisciplinary team of **more than 2,400 people** driven by the same values: excellence, optimism and non-conformism. The whole team puts its talent and passion into developing the most innovative vaccines and biotech services to create a positive impact on global health.

HIPRA's pillars of **CREDIBILITY**



EXCELLENCE
as your hallmark



OPTIMISM
as our way of being



NON-CONFORMISM
by nature

HIPRA

HIPRA AROUND THE WORLD

AFRICA

- Morocco
- South Africa

AMERICA

- Argentina
- Brazil
- Canada
- Colombia
- United States
- Mexico
- Peru
- Uruguay

EUROPE

- Germany
- Austria
- Belgium
- Denmark
- Spain **Central HQ**
- Slovakia
- France
- Greece
- Ireland
- Italy
- Luxembourg
- Norway
- Netherlands
- Portugal
- Poland
- United Kingdom
- Czech Republic
- Russia
- Turkey
- Ukraine

ASIA

- China
- South Korea
- Philippines
- India
- Indonesia
- Japan
- Malaysia
- Pakistan
- Thailand
- Taiwan
- Vietnam

- Distributor countries
- Subsidiary countries

What we do

HIPRA, as a company committed to global health, focuses on providing innovative solutions to improve the health of people and animals. Thanks to the synergies created between the Human Health Division and the Animal Health Division, it is in a unique position to understand and prevent zoonotic diseases.

02.

Human health

Arising out of the COVID-19 pandemic and using its extensive experience in prevention for animal health, HIPRA marked a further step in its evolution with the creation of the Human Health Division.

Faced with that exceptional situation, it decided to contribute its know-how in the fight against the pandemic, with the development of a bivalent adjuvanted recombinant protein vaccine to deal with COVID-19.



**Progress in the development
of HIPRA's vaccine against COVID-19**


The evolution towards human health was definitive. The Division was strengthened with the acquisition of the biotech company **GoodGut**, **devoted to research and development of diagnostic tests for digestive illnesses**. So far it has developed three diagnostic products and has another three that are in the study phase.

Among the products being developed for human health is also a **project to research a new vaccine against the Respiratory Syncytial Virus (RSV)**, which causes bronchitis and pneumonia.

THERAPEUTIC AREAS



Digestive



Respiratory

Animal health

HIPRA is a world leader in prevention for animal health, being ranked **fifth worldwide in biological products**. It has a portfolio of more than 100 vaccines for various animal species, both production and companion animals, with a wide variety of biological goals.


HIPRA goes beyond the development of vaccines. It offers vets and farmers a wide range of services that **improve the vaccination experience**. The company also develops and offers diagnostic services such as **HIPRA Diagnos**, smart vaccination devices with the **Smart Vaccination®** service, or the HIPRASTATS data analysis service. And, as regards training, it offers the service of **HIPRA University** for and with professionals from the sector.



See all the latest developments
related to animal health

It currently has more
than 50 projects underway

SPECIES




Sheep




Fish



Goats



Pigs




Birds



Dogs



Rabbits



Cows

HIPRA

Without **innovation** there is no project

Thanks to the talent and passion of its team, **HIPRA is the company that has developed and launched the most vaccines in the market in the last ten years, with a total of 22.**

To that end, it invests 10% of its annual turnover in research and 16% of its workforce belongs to the R&D and Recording department. This is a multidisciplinary team made up of graduates in pharmacy, veterinary science, biology, chemistry, and biotechnology, among others, who work together to develop innovative solutions that contribute to global health.

The company has a singular model with unique know-how that makes it a benchmark since it **controls all the phases of creation of a vaccine: from research and development to production and marketing.**

Biotechnology has facilities measuring more than 105,000 m² which are equipped with the latest technological advances and have the **good manufacturing practices (GMP)** certification from the European Union, United States and Japan, among others.

HIPRA complements its knowledge by creating **synergies with research centres and leading hospitals.** Its solutions reach more than 100 countries thanks to its marketing and sales team that is spread across 40 countries around the world.

Research is the basis of our knowledge



HIPRA

Sustainability

Respect for the environment is key for HIPRA. The company focuses on caring for the environment, trying to **minimise the impact of its activity**, ensuring that it does not compromise the natural resources of the future. To that end, it has an Environmental Policy that guarantees its commitment to acting in the most respectful way towards the environment.

CSR

HIPRA is committed to the health and well-being of its team and their families, as well as to the communities and environment where it operates.

HIPRA supports the **United Nations Declaration of Human Rights and the principles of the United Nations Global Compact** and ensures compliance with them through agreements with international and local entities that share the same objectives.



Purchase 100% of the electrical energy from our production sites, using only clean and renewable sources.



Calculation of carbon footprint to reduce CO₂ gas emissions.



Definition of a responsible Travel Policy.



Improvement of the correct separation and recycling of waste.



Awareness raising and information for staff about environmental and sustainability issues.



Investment aimed at reducing water consumption.

HIPRA

Building Immunity
for a Healthier World